Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Immunotherapy
Scientists at University of Erlangen, Department of Internal Medicine describe research in immunotherapy
April 15th, 2009
Research findings, 'Characterization of MHC class-I restricted TCRalphabeta+ CD4- CD8- double negative T cells recognizing the gp100 antigen from a melanoma patient after gp100 vaccination,' are discussed in a new report. "The immune attack against malignant tumors require the concerted action of CD8+ cytotoxic T lymphocytes (CTL) as well as CD4+ T helper cells. The contribution of T cell receptor (TCR) alphabeta+ CD4-CD8-double-negative (DN) T cells to anti-tumor immune responses is widely unknown," investigators in Erlangen, Germany report. "In previous studies, we have demonstrated that DN T cells with a broad TCR repertoire are present in humans in the peripheral...
Source: Vaccine Weekly (2009-04-15)
|
